Research study focused on the safety and efficacy of Lutetium-177-PSMA-I&T in Metastatic Castration-Resistant Prostate Cancer

If you are eligible for the Curium ECLIPSE research study, you will be randomly assigned to receive either Lutetium Lu-177-PSMA-I&T or standard-of-care hormone therapy. During the research study, you will visit the study site to receive treatment, blood tests, and imaging exams and you will be monitored for progression of your disease. Once the treatment portion of the study has ended, the study team will continue to follow up with you for up to five years.

This study of Lutetium Lu-177-PSMA-I&T, a radiopharmaceutical, is being performed for research purposes only. The safety and effectiveness of Lutetium Lu-177-PSMA-I&T have not been established by the FDA. It cannot be promised that patients will receive any medical benefits from participating in this study. Patients will be compensated for their time. However, your participation in this study could help lead to the approval of a new treatment for metastatic castration-resistant prostate cancer.

To find out if you may be eligible for the research study, please fill out the pre-screening questionnaire by clicking “Begin eligibility check”. If the questionnaire identifies you as a potential participant, you will be contacted by a member of the study team to gather more information and determine the closest study site to you. As part of the screening process, you may be asked to provide your medical history and travel to the study site for lab assessments and imaging exams.